About NovaDigm Therapeutics
NovaDigm Therapeutics is a biotechnology company focused on developing immunotherapeutics and preventative vaccines for fungal and bacterial diseases. Their main product, NDV-3A, is a vaccine candidate designed to reduce the severity of diseases caused by pathogens such as Candida and Staphylococcus aureus, including drug-resistant strains. The company's primary market includes healthcare providers and patients dealing with recurrent or life-threatening fungal and bacterial infections. It is based in Grand Forks, North Dakota.
NovaDigm Therapeutics Patents
NovaDigm Therapeutics has filed 5 patents.
Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes
Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes
Latest NovaDigm Therapeutics News
Mar 2, 2021
Search jobs 02-Mar-2021 Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Global Candidiasis Market , by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 873.8 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights. Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/229 Increasing prevalence of candidiasis is expected to fuel growth of the global candidiasis market over the forecast period. For instance, according to the study, ‘National Burden of Candidemia, United States, 2017, published in November 2018, in the journal Open Forum Infectious Diseases, invasive candidiasis (candidemia) is one of the most common bloodstream infections in the U.S. and the average incidence for the disease was around 9 per 100,000 people during 2013–2017. R&D of new vaccines for the treatment of candidiasis is expected to boost growth of the global candidiasis market over the forecast period. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice. Quick Buy – Candidiasis Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/229 Increasing number of clinical trials related to the treatment of fungal diseases is expected to propel growth of the global candidiasis market. For instance, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe. Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2018, Viamet Pharmaceuticals (NC), Inc. acquired Viamet Pharmaceuticals. The acquisition included the company’s product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection. Similarly, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center. Browse 40 Market Data Tables and 38 Figures spread through 178 Pages and in-depth TOC on “Candidiasis Market”- Global Forecast to 2026 by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the global candidiasis market press release, click the link below: https://www.coherentmarketinsights.com/press-release/candidiasis-market-to-surpass-us-13072-million-by-2026-2454 Key Takeaways The global candidiasis market is expected to exhibit a CAGR of 4.6% over the forecast period Among drug class, the azoles segment held dominant position in the global candidiasis market in 2017. Azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis. Among type, the vaginal candidiasis segment held dominant position in the global candidiasis market in 2017, owing to R&D in this segment Among route of administration, the oral segment held dominant position in the global candidiasis market in 2017. Several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form. Major players operating in the global candidiasis market include Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/229 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services. To know more about us, please visit our website – www.coherentmarketinsights.com Contact:
NovaDigm Therapeutics Frequently Asked Questions (FAQ)
Where is NovaDigm Therapeutics's headquarters?
NovaDigm Therapeutics's headquarters is located at 4201 James Ray Drive, Grand Forks.
What is NovaDigm Therapeutics's latest funding round?
NovaDigm Therapeutics's latest funding round is Series B.
How much did NovaDigm Therapeutics raise?
NovaDigm Therapeutics raised a total of $35.16M.
Who are the investors of NovaDigm Therapeutics?
Investors of NovaDigm Therapeutics include Domain Associates.
Who are NovaDigm Therapeutics's competitors?
Competitors of NovaDigm Therapeutics include Immunomic Therapeutics, Adamas Pharmaceuticals, Phico Therapeutics, CoImmune, Intarcia Therapeutics and 7 more.
Compare NovaDigm Therapeutics to Competitors
Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
Traversa Therapeutics is a company that operates in the healthcare sector, with a focus on developing therapeutic treatments. The company's main offerings include the development and provision of various therapeutic treatments designed to address different health conditions. It was founded in 2006 and is based in La Jolla, California.
BlueWillow Biologics operates as a clinical-stage biopharmaceutical company focused on developing intranasal vaccines and anti-infective products. The company offers a patented nanotechnology platform that produces oil-in-water nanoemulsions for intranasal vaccines and topical antiseptic applications, aiming to elicit mucosal and systemic immune responses. BlueWillow Biologics primarily serves the healthcare sector, with a focus on infectious diseases and allergy immunotherapy. It was founded in 1999 and is based in Ann Arbor, Michigan.
NAICONS (New Anti-Infective CONSortium) is a new organization aiming at integrating resources in the field of infectious diseases to create a strategic and operative hub dedicated to discover and develop antibiotics targeting unmet medical needs.